Sequenom Officials Discuss Plans for Low-Cost NIPT | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom officials on Thursday elaborated on the firm's plans to develop a lower-cost noninvasive prenatal test for fetal aneuploidy.

The new test will be targeted toward the international and low-risk markets and will run on a different platform than its MaterniT21 Plus test, which is targeted at high-risk pregnancies and runs on Illumina's HiSeq 2000 sequencer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.